An Open, One-sequence, Three-period Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Oral Single Dosing of Two Different Solid Formulations of GS-248
Latest Information Update: 02 Sep 2021
Price :
$35 *
At a glance
- Drugs Vipoglanstat (Primary)
- Indications Vascular disorders
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Gesynta Pharma
- 09 Nov 2020 Status changed from planning to completed.
- 12 Apr 2019 New trial record